NCT01685801View on ClinicalTrials.gov

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Cystic Fibrosis
Interventions
DRUG

Ivacaftor

150 milligram (mg) tablet orally every 12 hours up to 12 weeks.

DRUG

Placebo-matched-to-ivacaftor tablet

Orally every 12 hours up to 4 weeks.

Trial Locations (1)

Unknown

Denver

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT01685801 - Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function | Biotech Hunter | Biotech Hunter